The United States approves eye drops that correct tired eyes for 10 hours.

The U.S. Food and Drug Administration (FDA) has approved Lenz Therapeutics' Vizz eye drops for the treatment of presbyopia , or tired eyes, in adults, and they are expected to be available in U.S. pharmacies beginning in October 2025.

The pharmaceutical company has highlighted that these eye drops, based on the compound aceclidine, improve near vision in people with presbyopia for 10 hours with a single application per day, which could be a "radical change" for millions of people suffering from vision loss associated with aging .

Aceclidine, the base of this eye drop, works by constricting the pupil, but with minimal stimulation of the ciliary muscle. Vizz contracts the iris sphincter muscle, producing a pinhole effect and achieving a pupil of less than 2 mm, which expands the depth of focus to significantly improve near vision without causing myopic deviation, the company explains in a statement.

"I believe this will be a very useful solution for both optometrists and ophthalmologists , who will now be able to offer a highly effective and sought-after presbyopia treatment that could immediately become the standard," said Marc Bloomenstein, a clinical investigator for Vizz from the Schwartz Laser Eye Care Center in Arizona.

The FDA's approval of Vizz is based on the results of the Phase 3 Clarity 1 and Clarity 2 studies, which evaluated the product's safety and efficacy in 466 participants receiving once-daily dosing for 42 days, and Clarity 3, which studied its long-term safety in 217 participants receiving once-daily dosing for six months.

The pharmaceutical company has indicated that, in the first two studies, Vizz met all proposed objectives, demonstrating its ability to improve near vision in 30 minutes and lasting up to 10 hours. The vision improvement was reproducible and consistent in both trials.

Vizz was also well tolerated, with no serious treatment-related adverse events observed during more than 30,000 days of treatment in the three Clarity trials. The most common adverse reactions reported by participants were application site irritation, blurred vision, and headache. Most adverse reactions were mild, transient, and resolved spontaneously.